Outcomes of Adults with Acute Lymphoblastic Leukemia After Autologous Hematopoietic Stem Cell Transplantation and the Significance of Pretransplantation Minimal Residual Disease
Autor: | Shulian Chen, Yigeng Cao, Sizhou Feng, Erlie Jiang, Chen Liang, Aiming Pang, Jianfeng Yao, Qiaoling Ma, Zhe Ding, Xiao-Yu Zhang, Mingzhe Han, Jialin Wei |
---|---|
Rok vydání: | 2015 |
Předmět: |
Adult
Male Oncology China medicine.medical_specialty Neoplasm Residual Adolescent medicine.medical_treatment lcsh:Medicine Kaplan-Meier Estimate Hematopoietic stem cell transplantation Single Center Autologous Hematopoietic Stem Cell Transplantation Disease-Free Survival Young Adult hemic and lymphatic diseases Internal medicine medicine Humans Transplantation Homologous Acute Lymphoblastic Leukemia Minimal Residual Disease Prognostic Factors Survival analysis Proportional Hazards Models Retrospective Studies business.industry Proportional hazards model lcsh:R Hematopoietic Stem Cell Transplantation Retrospective cohort study General Medicine Middle Aged Precursor Cell Lymphoblastic Leukemia-Lymphoma Prognosis Minimal residual disease Surgery Transplantation Adult Acute Lymphoblastic Leukemia Female Original Article business |
Zdroj: | Chinese Medical Journal, Vol 128, Iss 15, Pp 2065-2071 (2015) Chinese Medical Journal |
ISSN: | 0366-6999 |
Popis: | Background: The postremission therapies for adult patients generally contain consolidation chemotherapy, allogeneic hematopoietic stem cell transplantation and autologous hematopoietic stem cell transplantation (auto-HSCT). Because of the various results from different centers, the optimal therapy for adult acute lymphoblastic leukemia (ALL) patients is still uncertain. This study aimed to better understand predictive factors and role of auto-HSCT in the postremission therapy for adult ALL patients. Methods: The outcomes of 135 adult patients with ALL, who received the first auto-HSCT in Hematopoietic Stem Cell Transplantation Center of Blood Diseases Hospital, Chinese Academy of Medical Sciences from January 1, 1994 to February 28, 2014, were retrospectively analyzed. Survival curves were estimated using the Kaplan-Meier method and simultaneous effects of multiple covariates were estimated with the Cox model. Results: Overall survival (OS) and disease-free survival (DFS) at 5 years for the whole cohort were 59.1 ± 4.5% and 59.0 ± 4.4%, respectively. The cumulative nonrelapse mortality and relapse rate at 5 years were 4.5 ± 0.03% and 36.6 ± 0.19%. For both OS and DFS, acute T-cell lymphoblastic leukemia, high lactate dehydrogenase (LDH) at diagnosis, blast cell proportion ≥5% on the 15 th day of induction therapy, and extramedullary infiltration before HSCT were the poor prognosis factors. In addition, age ≥35 years predicted poor DFS. Only T-ALL and high LDH were the independent undesirable factors associated with OS and DFS in Cox regression model. For 44 patients who had results of pretransplantation minimal residual disease (MRD), positive MRD (MRD ≥0.01%) indicated poor OS (P = 0.044) and DFS (P = 0.008). Furthermore, for the standard risk group, the patients with negative MRD (MRD |
Databáze: | OpenAIRE |
Externí odkaz: |